FibroBiologics, Inc. Common StockFBLGNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | -526.85% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | -618.71% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | -500.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | -500.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +9.31% | +17.79% | +18.08% | +28.51% | +28.43% |
| Weighted Average Shares Diluted Growth | +9.31% | +17.79% | +18.08% | +28.51% | +28.43% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +39.12% | +0.24% | +56.05% | -16.48% | -41.51% |
| Book Value per Share Growth | +99.69% | +0.00% | +0.00% | -96.45% | +75.26% |
| Debt Growth | +504.06% | +237.57% | +486.93% | +355.38% | -77.16% |
| R&D Expense Growth | +75.42% | +85.42% | +109.33% | +129.93% | -41.22% |
| SG&A Expenses Growth | +38.02% | +10.48% | +8.89% | -5.66% | -23.90% |